Leading experts have raised concerns that NHS delays could harm patients if Britain is pressured by President Donald Trump to increase payments for medications. There are fears that a proposed 25% hike in drug prices could strain the NHS budget, resulting in longer wait times for patients. The NHS’s strong negotiating power has historically allowed it to secure more affordable drug prices compared to private hospitals in the US.
Reports suggest that the UK government is considering raising the NHS’s “value for money” threshold by 25%, potentially leading to billions of pounds in additional spending on essential drugs. Following Trump’s threats, several pharmaceutical companies, including AstraZeneca, Lilly, and Merck, have paused significant investments in Britain, totaling over £1.3 billion.
Negotiations with US officials are ongoing to prevent the imposition of tariffs on drug imports. However, the outcome of these discussions remains uncertain. Experts like Professor Ed Wilson from Exeter University caution that increasing drug prices could result in trade-offs that negatively impact NHS patients, affecting treatment access and quality of care.
The pharmaceutical industry’s influence in these discussions has raised concerns about potential implications for public health. Critics argue that any threshold increase should prioritize population health rather than geopolitical or industry pressures. President Trump’s stance on drug pricing emphasizes the need for countries like the UK to contribute more to drug development costs.
The UK government emphasizes the importance of collaboration with the US to support pharmaceutical exports and enhance conditions for drug companies in the UK. NICE, responsible for assessing drug cost-effectiveness, acknowledges ongoing government deliberations on medicine expenditure levels within the healthcare system. These developments underscore the complex interplay between healthcare priorities, industry interests, and international trade dynamics.